RESUMEN
OBJECTIVE: To examine the prevalence of female sexual dysfunction (FSD) in gynecologic cancer survivors. METHODS: A cross-sectional observation survey recruited women aged 18-65 years old who were diagnosed with gynecologic cancers and underwent surgery, radiation, chemotherapy, or combined modalities. Data were collected from September 2019 to March 2020 by the Thai version of the female sexual function index questionnaire to define FSD. The survey contained six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. RESULTS: Of the 98 women included in the study, the mean age was 48.7 ± 10.6 years old. Two-third (67.3%) of the participants was premenopausal, had been diagnosed with ovarian cancer, and had early-stage gynecologic cancers. Fifty-eight of 98 (59.2%) participants were sexually active in the past 4 weeks before the survey. Among those, 89.6% had FSD. The median scores in the FSD group were significantly lower than those in the non-FSD group in all six domains, namely, desire, arousal, lubrication, orgasm, satisfaction, and pain (p < 0.05). There was no statistically significant difference observed between participants with and without FSD in terms of age group, cancer-related data, or sexual behavior data, except participants who had good/excellent relationships with their partners, which impacted FSD (p = 0.01). CONCLUSIONS: This study discovered the high prevalence (89.6%) of hidden issue of "female sexual dysfunction" in Thai gynecologic cancer survivors. The good/excellent relationships with their partners affected the FSD who were sexually active in the past 4 weeks before the survey.
Asunto(s)
Neoplasias de los Genitales Femeninos , Disfunciones Sexuales Psicológicas , Adolescente , Adulto , Anciano , Estudios Transversales , Femenino , Humanos , Persona de Mediana Edad , Conducta Sexual , Disfunciones Sexuales Psicológicas/epidemiología , Disfunciones Sexuales Psicológicas/etiología , Encuestas y Cuestionarios , Sobrevivientes , Tailandia , Adulto JovenRESUMEN
Objective: To evaluate the correlation of neonatal thyroid stimulating hormone (TSH) between iodine supplemented and no-iodine supplemented pregnant women. Material and Method: The present study was a prospective randomized controlled trial (RCT) that was taken at ANC unit, labor ward, and neonatal unit at Siriraj Hospital, Mahidol University, Bangkok, Thailand. Two hundred sixty six pregnant women were recruited between June 15, 2015 and July 31, 2016. They were randomized into two groups, iodine and no-iodine supplemented group. Results: No statistical significant of demographic data, original habitant areas, and adverse neonatal outcomes including preterm labor and low birthweight, of the pregnant patient between these two groups. Only the median value of neonatal TSH level was 3.44 and 3.95 mIU/l in iodine and no-iodine supplemented group, respectively, which was statistically significant different between the two groups (p-value <0.05). However, there were no clinical difference between the two groups. Conclusion: The present study presented that there was statistical significant difference of the median value of neonatal TSH level between two groups of iodine and no-iodine supplement pregnant women. Even if there was no clinically significant difference and none of the newborn was diagnosed of hypothyroidism, iodine supplementation in all pregnant women should be of concerned. A large prospective study would benefit the iodine implementation of pregnant women in Siriraj Hospital.